Cited by 353Iron Metabolism and DisordersFerroptosis and cancer prognosisNeurological diseases and metabolism

Targeting iron metabolism in drug discovery and delivery

Open access
Crielaard, Bart J., Lammers, Twan, Rivella, Stefano·2017·Nature Reviews Drug Discovery

Abstract

Iron fulfils a central role in many essential biochemical processes in human physiology; thus, proper processing of iron is crucial. Although iron metabolism is subject to relatively strict physiological control, numerous disorders, such as cancer and neurodegenerative diseases, have recently been linked to deregulated iron homeostasis. Consequently, iron metabolism constitutes a promising and largely unexploited therapeutic target for the development of new pharmacological treatments for these diseases. Several iron metabolism-targeted therapies are already under clinical evaluation for haematological disorders, and these and newly developed therapeutic agents are likely to have substantial benefit in the clinical management of iron metabolism-associated diseases, for which few efficacious treatments are currently available.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd.2016.248

Cites

353 of 353 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Although several approaches to restore aberrant FPN function have been evaluated in clinical trials, none have thus far succeeded.

    “Although several approaches to restore aberrant FPN function have been evaluated in clinical trials 16-18 , none have thus far succeeded.”
  • In preclinical models of anemia of inflammation, hepcidin antagonists decreased hepcidin expression, an effect verified in clinical trials for some compounds.

    “In preclinical models of anemia of inflammation, hepcidin antagonists decreased hepcidin expression, an effect verified in clinical trials for some compounds.133”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 1

  1. [224]Hartman CS AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia Proceedings of the American Society of Nephrology Kidney Week 2011

Cited by

Sorted by citations

Authors
Crielaard, B. J., Lammers, T., & Rivella, S.
Affiliations
  • University Medical Center Groningen (NL)
  • Utrecht University (NL)
  • Children's Hospital of Philadelphia (US)
Corresponding author
Crielaard, Bart J.
Venue
Nature Reviews Drug Discovery
Published
2017-02-03
Volume
16
Issue
6
Pages
400-423
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2584260978
Cited by
352
References
352
Citations by year
2026: 19 · 2025: 38 · 2024: 37 · 2023: 51 · 2022: 58 · 2021: 39 · 2020: 33 · 2019: 38 · 2018: 32 · 2017: 6 · 2016: 1
FWCI
4.70
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • University of Twente Research Information (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • University of Twente Research Information (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • La Jolla Pharmaceutical Company
  • Ionis Pharmaceuticals
  • European Commission (HORIZON2020, 707229)
  • Deutsche Forschungsgemeinschaft (309495, LA2937/1-2)
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK090554, R01DK095112)
  • H2020 European Research Council (680882)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
iron metabolism, iron homeostasis, drug delivery, hematologic disorders, cancer, neurodegeneration, therapeutic target
MeSH terms
Animals, Homeostasis, Humans, Iron, Neoplasms, Drug Design, Drug Delivery Systems, Neurodegenerative Diseases, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review